- Home
- IBRX vs RYTM Comparison
IBRX vs RYTM Comparison
Compare IBRX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | RYTM |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IBRX | RYTM |
|---|---|---|
| Price | $8.58 | $102.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $11.80 | ★ $129.92 |
| AVG Volume (30 Days) | ★ 32.9M | 657.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $680.06 | $47.98 |
| Revenue Next Year | $90.34 | $56.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $45.91 |
| 52 Week High | $8.28 | $122.20 |
Technical Indicators
Market Signals| Indicator | IBRX | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 72.34 | 47.56 |
| Support Level | $5.93 | $95.44 |
| Resistance Level | $7.30 | $104.50 |
| Average True Range (ATR) | 0.81 | 5.48 |
| MACD | -0.00 | -0.36 |
| Stochastic Oscillator | 96.61 | 41.59 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.